|
|
|
|
Learn how leveraging platform processes can enable flexible service at each level – pre-clinical through commercial – and reduce development timelines and costs on the path to market.
|
|
|
|
|
Delve into why investing in a comprehensive feasibility program for GOI testing is not just beneficial, but absolutely essential for cell and gene therapy companies.
|
|
|
|
|
Designing a CGT production process that is scalable and repeatable at cGMP quality is complex, but your journey can be eased by following the right strategy and working with an experienced partner.
|
|
|
|
|
There is a significant opportunity for NK cell-based therapies to continue to make a significant impact in patient care. Discover strategies for creating a cost-effective NK cell biopharma product.
|
|
|
|
|
As advanced therapies race forward, staying ahead is paramount. Harnessing technology, sponsors can unlock efficiencies and propel production to new heights.
|
|
|
|
|
These models are essential to process development as they allow developers to fine-tune each step without large investments in materials and consumables. Explore how to shorten timelines and advance your therapy to the clinical stage with speed and reduced costs.
|
|
|
|
|
|
|
|
|
|
|
|
Viral Vector Capabilities
|
Our scientists have extensive experience in viral vector-based gene therapy, specializing in adeno-associated viral vectors (AAV), lentiviral vectors (LVV), and retroviral vectors (RVV). We develop and manufacture viral vectors that meet commercial demands for gene therapy products.
|
|
• Request Information
|
|
|
|
|
|
|
|
|
|
|
|
